Think of ApoB as a more accurate measure of the risk associated with LDL, or ‘bad cholesterol.’ It reflects the number of particles that can form plaque in your arteries, giving you a clearer picture than the amount of cholesterol they carry alone.
By Brandon Ballinger • Updated
Think of ApoB as a more accurate way to measure the cardiovascular risk associated with “bad cholesterol.” ApoB predicts that risk more accurately than LDL cholesterol because it reflects how many plaque-forming particles are circulating in your blood.
The illustration below shows a lipoprotein: a particle carrying cholesterol and triglycerides, with proteins on its surface. LDL cholesterol measures the amount of cholesterol carried inside LDL particles. ApoB measures a protein on their surface, with one ApoB molecule per LDL particle.

Cholesterol travels inside lipoprotein particles, while apolipoproteins are part of their surface. Source: Cleveland Clinic, 2022.
Particles can carry different amounts of cholesterol. Two people with the same LDL cholesterol can therefore have different numbers of particles, and different risk. ApoB also captures other plaque-forming particles, including VLDL and IDL. Our ApoB vs LDL guide explains how these differences affect the comparison.
As Allan Sniderman of McGill University and colleagues put it in their 2025 editorial:
“An apoB particle is the basic unit of injury to the arterial wall—it is that simple.”
Sniderman, Pencina, and Thanassoulis, European Heart Journal, 2025.
Our analysis of 1,710 Empirical patients used ApoB ≥100 mg/dL and LDL <130 mg/dL to identify elevated ApoB despite lower LDL. In that cohort, 8% met both criteria. These analysis cutoffs aren’t personal treatment goals or an estimate of how many people will have a heart attack.

The upper-left group had ApoB of at least 100 mg/dL despite LDL below 130 mg/dL. Source: Empirical’s LDL–ApoB analysis.
We also compared modern LDL formulas with measured ApoB to see whether a better LDL estimate could close that gap. Testing Lp(a) can also identify inherited risk that a standard lipid panel doesn’t measure.
In practice, the people who benefit most from ApoB testing are those with high triglycerides, type 2 diabetes, or insulin resistance, and people already taking cholesterol-lowering medication whose LDL is at goal but whose cardiovascular risk remains high. In these situations, LDL cholesterol can understate the number of plaque-forming particles in the blood.
ApoB can help you and your clinician decide whether your current treatment is enough or whether to adjust it. The American Heart Association’s testing guidance highlights its usefulness in people taking cholesterol-lowering medication, especially those with cardiovascular disease, type 2 diabetes, or high triglycerides.
An ApoB below 90 mg/dL is desirable in Mayo Clinic Laboratories’ adult result categories. Your lab may use different cutoffs.
| ApoB (mg/dL) | Adult result category |
|---|---|
| Below 90 | Desirable |
| 90–99 | Above desirable |
| 100–119 | Borderline high |
| 120–139 | High |
| 140 or higher | Very high |
A lab category helps interpret a result. A treatment goal is the level you and your clinician aim for based on your risk of heart attack or stroke.
Your result appears in mg/dL. In the Empirical app, you can see it alongside previous measurements and a percentile comparison, as in the example below.
The app brings your ApoB result and history together; this screenshot uses example data.
The 2026 ACC/AHA dyslipidemia guidelines include ApoB goals below 90, 70, or 55 mg/dL. Selected examples:
| Clinical situation | ApoB goal |
|---|---|
| Diabetes without additional cardiovascular risk factors or diabetes-specific risk modifiers | Below 90 mg/dL |
| Diabetes with additional risk factors, or established atherosclerotic cardiovascular disease that isn’t very high risk | Below 70 mg/dL |
| Established atherosclerotic cardiovascular disease at very high risk | Below 55 mg/dL |
Your clinician chooses a goal using your history, other lipid results, and treatment. An ApoB of 85 mg/dL can be desirable on a lab report yet above your treatment goal of 70 mg/dL.
In our analysis of the CDC’s NHANES 2015–2016 ApoB data, the median ApoB was about 76 mg/dL for adults aged 18–29 and 88 mg/dL for adults aged 70 and older. These population percentiles show what’s common, not what your treatment goal should be.
The chart shows median ApoB and the 10th–90th percentiles for each age group and sex. Source: CDC NHANES, 2015–2016, weighted estimates.
High ApoB suggests more particles that can form plaque in your arteries. It doesn’t by itself diagnose a blockage. Contributors include inherited lipid disorders, insulin resistance, diet, and hypothyroidism. Review your result alongside LDL, triglycerides, blood pressure, and medical history to decide whether nutrition changes or medication would help.
Nutrition changes and medication can lower ApoB. Our guide to lowering ApoB covers the practical steps, including less saturated fat and more soluble fiber. Your clinician may recommend a statin or another ApoB-lowering medication depending on your starting level and goal. The illustration below shows where different medications act, from cholesterol absorption in the intestine to particle clearance by the liver.

Different medication classes act at different steps in cholesterol production, absorption, and clearance. Source: Nurmohamed et al., JACC, 2021.
You can explore how changes in cholesterol and other risk factors work together in our heart attack risk simulator.
When ApoB is guiding treatment, your clinician can recheck it with your follow-up lipid panel. The 2026 guidelines recommend lipid panels 4–12 weeks after starting or changing lipid-lowering therapy, then every 6–12 months. Whether to include ApoB each time depends on whether it will change your care.
Daniel Soffer of the University of Pennsylvania and colleagues summarize the evidence for testing before and during lipid-lowering therapy (LLT):
“ApoB has been shown to be superior to LDL-C in risk assessment both before and during treatment with LLT.”
Soffer et al., Journal of Clinical Lipidology, 2024.
Empirical offers an ApoB-only blood test for $49. For more context, the $190 comprehensive health panel includes ApoB, Lp(a), a lipid panel, hs-CRP, and 100+ biomarkers in total. The $399 advanced program adds two targeted re-tests over 12 months. New York and New Jersey have a $99 lab surcharge, bringing the standalone test to $148 and the panel to $289. Empirical accepts FSA/HSA payments.
ApoB is generally billed under CPT 82172. Insurance coverage depends on your plan and reason for testing; the prices above are Empirical’s self-pay prices.
ApoB itself doesn’t require fasting. Other tests in a panel may require it. Follow the instructions for your complete order; Empirical’s comprehensive panel calls for an 8–12-hour fast.
With Empirical, most results are available within 1-2 weeks after your blood draw. Some tests in the full panel can take longer. You’ll receive a notification in the app when results are ready. The comprehensive panel includes a doctor-reviewed written report.
ApoB is most highly correlated with Non-HDL Cholesterol and LDL Cholesterol. Here are the top biomarkers correlated with ApoB, based on 500,000 tests done by Empirical Health.
The percentage shows how strongly two biomarkers move together. A higher number means the relationship is stronger. Green = rises and falls together. Orange = one rises as the other falls.
ApoB is drawn at 2,200+ Quest and BioReference patient service centers across the US, so there's usually one within a short drive. Pick your state to see the metros we cover and every location in it.
Explore our testing network, then search your ZIP code for nearby labs and addresses. Map pins show approximate locations; confirm the address and hours before visiting.
Find a lab near you